BridgeBio Pharma Inc

Their new heart medicine Attruby absolutely crushed expectations, making three times more money than experts predicted in its first quarter. Over 1,000 patients got prescriptions in just three months, and 95% of people who try it keep using it. This shows the medicine really works and doctors trust it.

Attruby works better than competitors - it reduces death rates by 42% compared to 30% for the main rival. Plus it's cheaper and comes as a pill instead of requiring hospital visits for injections. When you're 77 years old on average, taking a pill at home is way better than going to the hospital.

Almost all their money comes from this single drug right now. If something goes wrong with Attruby - like competitors stealing customers or insurance companies refusing to pay - the whole company could be in trouble. They're basically betting everything on one product.

They're spending huge amounts of money testing three new drugs that might not work. If these experiments fail, they'll have burned through hundreds of millions of dollars with nothing to show for it. Biotech drug testing is basically expensive gambling with people's lives.